(Total Views: 534)
Posted On: 08/12/2020 9:01:17 PM
Post# of 153831
Quote:
The second point (I don't believe I misunderstood), was that NEWS2 can be made primary endpoint in a phase 3 and would have statistical significance with trial size in phase 2 CD10 as that is exactly what Cytodyn achieved.
I agree w/ regards to the NEWS2 being a primary endpoint. Not debating that. But I'm pretty sure he spoke of a larger trial size to achieve greater statistical significance.
All good.
(0)
(1)
